One stock that might be an intriguing choice for investors right now is Isis Pharmaceuticals, Inc. (ISIS). This is because this security in the Med-Biomed/Generic industry space is seeing solid earnings estimate revision activity, and is in …
To drive ISIS from the West Bank, even Hamas cooperates with the Israelis ... There is visceral hatred, but also a common humanity, which is a far cry from Rachel …
There's money going out, not just coming in." 3 divisions worth: ISIS's stock of weapons and equipment "When you look at them as a conventional force, they have approximately at least three divisions — if you think of a Western military …
ISIS Power is not the only brand to relinquish its name in the wake of the negative association with the militant organization. Last month, Belgian chocolate-maker ISIS changed its name to Libeert after some customers refused to …
Isis Pharmaceuticals, Inc. (ISIS) was a big mover last session, as the company saw its shares rise by nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues …
Many of the enlistees arrayed around the screens are in their 20s and might pass for stock traders or Google employees were ... assumed an increasingly central role …
Take ISIS Pharmaceuticals. This $4.3 billion biotech firm surged 10% today, and it's up 43% in the last three months. According to Nasdaq, the stock price crossed above its 200-day moving average for the first time since early spring. …
Our View A rapid increase in terror attacks along with the widespread rise of ISIS has compelled nations across the globe to strengthen arsenal and bump up the …
The crowd surged forward and men yelled when someone tried to cut in. They came from the ISIS side to stock up on cooking gas and groceries, as supplies in their home towns have dried up sinceISIS fighters captured the area about …
Ionis’ decision is understandable, especially given the publicly-traded company appears as “ISIS” on stock exchange tickers; not exactly an attractive target for potential investors. “Our goal is to create medicines that will save patients’ …